Healthcare / Medical Instruments & SuppliesTaiwan
$196.50
-3.00 (-1.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-137.9M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.5B
P/E
15.6x
↓EV/EBITDA
8.4x
↓ROE
18.6%
↑Gross Margin
40.9%
↓Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+23.9%
FCF CAGR
—
FCF margin
-4.0%
FCF / Net income
-0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.49B · net income $740.8M · FCF $-137.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.49B | $3.49B | $3.00B | $2.57B | $1.83B |
| Net Income | $740.8M | $740.8M | $669.6M | $562.3M | $313.0M |
| EBITDA | $1.44B | $1.44B | $1.30B | $1.13B | $628.5M |
| EPS | — | — | 11.61 | 10.49 | 5.85 |
| Gross Margin | 40.9% | 40.9% | 39.3% | 39.9% | 38.0% |
| Operating Margin | 28.8% | 28.8% | 29.1% | 28.5% | 26.5% |
| Net Margin | 21.2% | 21.2% | 22.3% | 21.9% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.40 | 0.40 | 0.38 | 0.97 | 0.47 |
| Current Ratio | 2.57 | 2.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-137.9M | $-137.9M | $197.4M | $-435.2M | $465.7M |
| Returns | |||||
| ROE | 18.6% | 18.6% | 19.0% | 31.5% | 19.1% |
| Valuation | |||||
| P/E | 15.63 | 15.63 | 14.64 | 23.88 | 22.48 |
| EV/EBITDA | 8.37 | 8.37 | 7.63 | 12.67 | 10.94 |
| P/B | 2.89 | 2.89 | 2.77 | 7.51 | 4.29 |
| Growth & Yield | |||||
| Revenue Growth | 16.2% | 16.2% | 16.7% | 40.2% | — |
| EPS Growth | — | — | 10.7% | 79.3% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.7%
Start / end P/E
n/dx → n/dx
EPS bridge
11.61 → n/d
Residual
-6.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.